If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Zacks Equity Research
·3-min read

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.

The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.

What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?

Halozyme Therapeutics' Business In-Depth

With that in mind, let's take a look at Halozyme Therapeutics' main business drivers.

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.

The company’s ENHANZE drug delivery technology helps in developing SC formulation of drugs. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing SC formulation of their currently marketed drugs.It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform. The company currently earn royalties on sales of seven commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).

In May 2022, Halozyme acquired Antares Pharma which added an industry-leading auto-injector platform and a commercial business with two proprietary products to Halozyme’s portfolio.

The company’s portfolio of products include — Hylenex Recombinant and Xyosted. Halozyme also has an ongoing early-stage study evaluating ATRS-1902 for treating adrenal crisis. ATRS-1902 was granted Fast Track designation by the FDA for adrenal crisis rescue in 2022.

Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. The company generated total revenues of $829.3 million in 2023, up 26% year over year.

Bottom Line

Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Halozyme Therapeutics a decade ago, you're probably feeling pretty good about your investment today.

A $1000 investment made in July 2014 would be worth $5,531.38, or a 453.14% gain, as of July 10, 2024, according to our calculations. Investors should note that this return excludes dividends but includes price increases.

The S&P 500 rose 182.69% and the price of gold increased 70.03% over the same time frame in comparison.

Analysts are anticipating more upside for HALO.

Halozyme is riding on the success of the collaboration deals related to its ENHANZE technology with several large pharma companies. Robust demand for the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo is significantly boosting royalties and driving the top line. The momentum is likely to continue in 2024. The company is also focused on signing new collaboration deals to aid growth further. The ongoing studies on partnered pipeline candidates are progressing well. However, blockbuster drugs like Herceptin and Rituxan that use ENHANZE technology have now started facing biosimilar competition, which is eroding revenues from royalties. High dependence on partners for revenues in the form of royalties and collaborative agreements is a woe. Any deal termination from partners will be a major setback.

Over the past four weeks, shares have rallied 5.93%, and there have been 4 higher earnings estimate revisions in the past two months for fiscal 2024 compared to none lower. The consensus estimate has moved up as well.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

  • Up next
  • Up next
  • Up next
  • Up next

Latest stories

  • Stocks rise as US inflation data boosts rate cut hopes

    Major stock markets pushed higher Friday as traders welcomed data showing a moderation in US inflation, firming expectations the Federal Reserve will start cutting interest rates in September.The inflation data followed figures Thursday that showed the US economy expanded far more than expected in the second quarter, providing a much-needed boost to sentiment and easing concerns that it was slowing a little too much for comfort.

  • Malaysian market wins over investors as Thai equities lose lustre from political instability, fewer tourists

    BANGKOK, July 27 — For years, Thai equities were among Southeast Asia’s largest stock markets. However, Malaysia and Sin...

  • 3 Electronics Stocks to Buy From a Challenging Industry

    Electronics stocks like KLA (KLAC), Flex (FLEX) and Daktronics (DAKT) are expected to benefit from investments in infrastructure and expanded capacity despite macroeconomic headwinds.

  • TSMC leads chipmaker plunge as trade resumes after typhoon pause

    Taiwanese giant TSMC tumbled with several other leading chip makers Friday as traders returned from a typhoon-imposed two-day break to play catch-up with a global tech rout.The rally in all things tech helped TSMC, which is also listed in New York, to briefly break the US$1 trillion market capitalisation barrier this month, putting it ahead of Tesla as the seventh most valuable technology firm. 

  • Why Investors Need to Take Advantage of These 2 Computer and Technology Stocks Now

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

  • Altria (MO) Hits 52-Week High: Time to Cash In or Hold Steady?

    Altria's (MO) strategic moves into smoke-free products offer growth potential, though the declining cigarette business raises concerns.

  • Stocks to watch next week: Meta, Apple, Amazon and also UK interest rates

    Earnings preview of key companies reporting next week and what to look out for

  • Shell (SHEL) Q2 Earnings Coming Up: Here's What to Expect

    Shell (SHEL) beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, resulting in an earnings surprise of 9.2%, on average.

  • Here is What to Know Beyond Why IonQ, Inc. (IONQ) is a Trending Stock

    Recently, Zacks.com users have been paying close attention to IonQ (IONQ). This makes it worthwhile to examine what the stock has in store.

  • Core Laboratories (CLB) Q2 Earnings Beat & Revenues Lag

    Core Laboratories (CLB) expects Reservoir Description revenues of $86.5-$89.5 million and Production Enhancement revenues of $44.5-$47.5 million for the third quarter of 2024.

  • Investors Are Suddenly Getting Very Concerned That AI Isn't Making Any Serious Money

    An increasing number of Silicon Valley investors and Wall Street analysts are starting to ring the alarm bells over the billions of dollars being invested in AI, an overconfidence that could result in a massive bubble. As the Washington Post reports, investment bankers are singing a dramatically different tune than last year, a period marked […]

  • Why Coupang, Inc. (CPNG) Outpaced the Stock Market Today

    In the most recent trading session, Coupang, Inc. (CPNG) closed at $20.18, indicating a +1.97% shift from the previous trading day.

  • Capgemini forecasts surprise revenue fall on automotive, aerospace downturn

    French IT group Capgemini forecast a surprise fall in annual revenue on Friday, citing a downturn in the automotive and aerospace sectors, sending its shares tumbling more than 9%. Shares of Capgemini fell 9.4% by 0728 GMT to hit the bottom of the CAC40 index, after the Paris-based group said it now expects its organic sales to fall between 0.5% and 1.5% in 2024, compared with the 0-3% rise previously forecast. "The slope of recovery in the second half will be affected by the recent deterioration of the outlook in the automotive and aerospace sectors and the slower recovery in financial services," CEO Aiman Ezzat said in a statement.

  • Datadog (DDOG) Falls 7.2% MTD: Should Investors Buy the Dip?

    Datadog's (DDOG) innovative portfolio and an expanding partner base make it an attractive investment opportunity.

  • What retail investors want to know about markets right now

    It was a rocky week for stocks, with the Dow Jones Industrial Average being the only of the big three indexes (^DJI,^GSPC, ^IXIC) to post a weekly gain. But retail investors have seemingly shrugged it off, Investopedia Editor-in-Chief Caleb Silver tells Yahoo Finance. Based on Investopedia's sentiment indicators, Silver thinks that, overall, the stock decline may not have lasted long enough for it to really register with individual investors. "Even though we have had these sort of pauses... this rotation is super healthy and I think investors that have been through a couple of cycles know this. They know that market breadth expansion is actually good for the overall health of the bull market," he says. So, what is Investopedia's audience interested in right now? The election, though Silver notes that it's "not necessarily about who wins as much as what kind of chaos can we expect in front of and during that election." He also notes there is interest in debt levels by president, inflation rates by president, and investing in small caps.  For more expert insight and the latest market action, click here to watch this full episode of Asking For A Trend. This post was written by Stephanie Mikulich.

  • 3 BlackRock Mutual Funds to Buy With Rate Cuts on the Horizon

    Invest in BlackRock mutual funds like BMCAX, BATPX and MRBVX for high returns and risk reduction as the first rate cut appears on the horizon.

  • Here's Why Paramount Global-B (PARA) is a Strong Value Stock

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

  • Toyota to build EV battery plant for Lexus cars, Nikkei reports

    TOKYO (Reuters) -Japan's Toyota Motor plans to build a battery plant for electric vehicles in the southwestern prefecture of Fukuoka and supply its batteries to a factory that makes luxury Lexus brand cars, the Nikkei business daily reported on Friday. The world's top-selling automaker would seek to make the island of Kyushu where Fukuoka is located a central part of its supply chain for battery-powered vehicles and an export base for Asia, the newspaper said. A Toyota spokesperson said the company was aware of the report, but that it was not something it had announced.

  • Berkshire (BRK.B) Rises 24% YTD: What Should Investors Do Now?

    Holding Berkshire (BRK.B) shares renders dynamism to shareholders' portfolio. Thus, investors who already hold Berkshire shares should retain the stock and others can wait for a better entry point.

  • Singapore home prices slow, rents fall in cooling market

    Singapore private home prices rose less than estimated and rents edged down in the second quarter, following government efforts to tame the real estate boom.